News Archive
Low-dose computed tomography (LDCT) lung cancer screening is recommended to screen patients with an increased risk of developing lung cancer, but little research regarding the emotional toll of screening has been conducted. Researchers from Stony Brook Cancer Center in Stony Brook, New York found 43 percent of patients undergoing LDCT experienced elevated distress before screening, and one-third of patients experienced continued distress even after being told there was no sign of cancer.
Nastech Pharmaceutical Company today announced that it has been awarded U.S. patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the Treatment and Prevention of Breast Cancer and Psychiatric Disorders."
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
Gulf War Illness (GWI)-the chronic health condition that affects about one in four military veterans of the 1991 Gulf War-appears to be the result of several factors, which differed in importance depending upon the locations where veterans served during the war, according to a Baylor University study.
PEPFAR's gender-based violence (GBV) initiative is bringing "new momentum" and attention to the intersection of HIV and GBV, Janet Fleischman, senior associate at the Global Health Policy Center of the Center for Strategic & International Studies (CSIS), writes in a post on the center's "Smart Global Health" blog.
› Verified 3 days ago